Measurement of central corneal thickness by ultrasound pachymetry and oculus pentacam in well controlled glaucoma patients: A hospital based comparative study

Polypoidal chorodial vasculopathy (PCV) is a disorder characterized by multiple, recurrent hemorrhagic exudative pigmented epithelium detachments (PED). It is controversial whether it is a distinct disorder, or a subtype of age related macular degeneration (AMD). When it was first described, it was thought to be an isolated choroidal vascular anomaly of posterior fundus. Lately it was defined as a type of choroidal neovascularization [1]. Nevertheless, PCV has different natural history and treatment response characteristics from exudative AMD. Presence of a polypoidal branching vascular network in the inner choroid causes the disorder. Treatment is with photodynamic therapy (PDT) or antivascular endothelial growth factor (VEGF) injections. In this report, a PCV case with PED, having a rapid response to switching from bevacizumab to aflibercept, is presented.